Home › BioCryst Pharmaceuticals Rating Lowered to Neutral at Zacks
 

Keywords :   


BioCryst Pharmaceuticals Rating Lowered to Neutral at Zacks

2013-02-08 05:07:24| Biotech - Topix.net

They currently have a $2.00 price target on the stock. A number of other analysts have also recently weighed in on BCRX.

Tags: rating neutral lowered pharmaceuticals

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.11 EVA 6
23.11 8
23.11SEVENTEEN ALWAYS YOURS Weverse 13
23.11 DX
23.11 No.23/1998
23.11 DVD 9
23.11
23.11 CD His Melody
More »